Adaptive Biotech (ADPT) Reports 35% Revenue Growth Driven by Strong clonoSEQ Performance in Q1 2026
Adaptive Biotechnologies (NASDAQ:ADPT) reported Q1 2026 revenue of $70.9 million, up 35% year over year, driven by its MRD business, which generated 95% of revenue and rose 53%. clonoSEQ test volume increased 41% to 32,595. Net loss narrowed to $20.0 million; non-GAAP Adjusted EBITDA loss was $2.5 million. The company raised full-year 2026 MRD revenue guidance to $260–$270 million.
How this was made
The 30-second read
Why it matters
The raised FY2026 MRD revenue guidance ($260–$270M) is the primary catalyst, supported by higher MRD revenue (+53% YoY), clonoSEQ test volume (+41%), and narrowed losses.
Market read
Material company-specific earnings/guidance update for ADPT with explicit FY2026 MRD revenue range.
What to watch
The article highlights cash and milestone revenue but does not provide gross margin, payer mix, or longer-term durability of test growth—key for valuation.
Background
Adaptive Biotechnologies’ MRD business (clonoSEQ) is a core driver; the article frames Q1 2026 performance and a guidance increase for FY2026 MRD revenue.
Ticker impact
Adaptive Biotechnologies reported Q1 2026 revenue +35% and raised full-year 2026 MRD revenue guidance to $260–$270M.
Likely positive bias for ADPT as investors re-rate growth and margin trajectory; magnitude depends on valuation vs raised guidance.
The article provides fresh, decision-relevant datapoints: Q1 revenue growth, clonoSEQ test volume, and an explicit full-year guidance increase.
Market effects
Strength in MRD/clonoSEQ adoption may modestly improve sentiment for liquid MRD diagnostics and personalized immune-testing peers.
Primarily US-listed biotech sentiment; limited direct regional spillover beyond healthcare/biotech investors.
MRD testing demand signal could be relevant to global oncology diagnostics adoption narratives, though article is US-focused.
Counterpoint
Revenue growth may be concentrated in MRD/clonoSEQ; investors may discount sustainability if clinical adoption or test volumes decelerate.
Key entities
- companyAdaptive Biotechnologies Corporation
Reports Q1 2026 revenue growth and raises full-year 2026 MRD revenue guidance based on clonoSEQ performance.
- productclonoSEQ
Flagship MRD test whose test volume rose 41% to 32,595 in Q1 2026.
- segmentMRD business
Minimal Residual Disease segment driving 95% of total revenue and +53% YoY growth in Q1 2026.
